MISSISSAUGA, ON, Oct. 8, 2019 /CNW/ - Today Amgen Canada announced that EVENITY ® (romosozumab) is now available in Canada for the treatment of osteoporosis in postmenopausal women at high risk for ...

EVENITY is an investigational bone-forming monoclonal antibody and is not approved by any regulatory authority for the treatment of osteoporosis. It is designed to work by inhibiting the activity of ...

Amgen, Inc. AMGN and its partner UCB announced that the FDA has approved Evenity (romosozumab-aqqg) for treating osteoporosis in postmenopausal women at high risk of fracture. Evenity is the first and ...

THOUSAND OAKS, Calif., Sept. 8, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that 19 scientific abstracts will highlight the latest scientific research on EVENITY™* (romosozumab) and ...

The US Food and Drug Administration has approved a new treatment for osteoporosis in postmenopausal women who are at high risk of bone fractures. The FDA announced Tuesday that the drug, called ...

Many medicines require refrigeration to remain effective, so travelers need to plan in advance to travel safely without affecting their treatment.

DUBLIN--(BUSINESS WIRE)--The "Osteoporosis KOL Interviews" report has been added to Research and Markets' offering. The author interviewed an endocrinologist based in the US and a rheumatologist based ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Osteoporosis ...

According to the Bone Health and osteoporosis foundation, 10 million Americans are living with the bone disease and 44 million have low bone density. Dr. Lacy Anderson talks about osteoporosis ...

Amgen Inc. AMGN and partner UCB announced that the European Commission (EC) has granted marketing authorization to Evenity (romosozumab) for the treatment of severe osteoporosis in postmenopausal ...

The US Food and Drug Administration has approved a new treatment for osteoporosis in postmenopausal women who are at high risk of bone fractures. The US Food and Drug Administration has approved a new ...